Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.81 |
| ▸ | USP2 | O75604 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18228404 | 1.00 | HPGD (0.96) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL1927946 | 0.98 | HPGD (1.00) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL436090 | 0.98 | HPGD (1.00) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL243236 | 0.98 | HPGD (1.00) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL8919062 | 0.98 | HPGD (1.00) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL27929296 | 0.98 | HPGD (1.00) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| Bicarbonate SCHEMBL1582960 | 0.96 | HPGD (0.96) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL9209631 | 0.96 | HPGD (0.96) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL1263133 | 0.95 | HPGD (0.88) | HPGDALDH1A1USP2MAPK1SIGMAR1 | |
| SCHEMBL2614241 | 0.93 | HPGD (0.84) | HPGDALDH1A1USP2MAPK1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119798265-A | Asymmetric synthetic pyrrole method for preparing lixivium alkaloid | 武汉大学深圳研究院 | 2025-04-11 | — | — | CN | claimed |
| CN-114805107-A | N-alpha position arylation method of nitrogen-containing heterocycle realized by photocatalysis | 哈尔滨工业大学（深圳） | 2022-07-29 | — | — | CN | claimed |
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | claimed |
| EP-2626358-B1 | Immunoassay for pyrrolidinophenones | RANDOX LAB LTD (GB) | 2015-09-02 | — | — | EP | claimed |
| US-20130210167-A1 | IMMUNOASSAY FOR PYRROLIDINOPHENONES | RANDOX LABORATORIES LIMITED (GB) | 2013-08-15 | — | — | US | claimed |
| EP-2626358-A1 | Immunoassay for pyrrolidinophenones | Randox Laboratories Ltd. (GB) | 2013-08-14 | — | — | EP | claimed |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | NOVARTIS AG (CH) | 2010-06-24 | — | — | US | claimed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | claimed |
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | BAESCHLIN DANIEL KASPAR | 2008-08-14 | — | — | US | claimed |
| EP-1915366-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | Novartis AG (CH) | 2008-04-30 | — | — | EP | claimed |
| EP-1841740-A1 | 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES | Novartis AG (CH) | 2007-10-10 | — | — | EP | claimed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | claimed |
| WO-2006128659-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS. | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | claimed |
| WO-2006117183-A1 | 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-09 | — | — | WO | claimed |
| WO-2006094763-A1 | 3,4,5-SUBSTITUTED PIPERIDINE COMPOUNDS | NOVARTIS AG (CH) | 2006-09-14 | — | — | WO | claimed |
| WO-2006074924-A1 | 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | claimed |
| WO-2006034196-A1 | COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR | LIFELIKE BIOMATIC INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | LIFELIKE BIOMATIC, INC. (US) | 2006-03-23 | — | — | US | claimed |
| US-5496844-A | Indole derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-03-05 | — | — | US | claimed |
| EP-0639567-A1 | INDOLE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1995-02-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | GRIN1, GRIN3A, GRIN2A | HPGD 1202/4885ALDH1A1 4321/4885USP2 3620/4885 |
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | HPGD 199/4885ALDH1A1 511/4885USP2 4856/4885 |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | HPGD 113/4885ALDH1A1 412/4885USP2 4728/4885 |
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | HPGD 501/4885ALDH1A1 39/4885USP2 4413/4885 |
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | REN, ACE, AGTR1 | HPGD 435/4885ALDH1A1 231/4885USP2 3632/4885 |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | REN, ACE, PIGO | HPGD 309/4885ALDH1A1 56/4885USP2 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.